[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de Guanajuato\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648606","effect-of-a-low-age-diet-on-liver-function-in-adults-with-fatty-liver-100648606",false,"NCT07723196","Effect of a Low AGE Diet on Liver Function in Adults With Fatty Liver.","Effect of a Diet Low in Advanced Glycation End Products on Liver Function and the Degree of Steatosis in Adults With Metabolic Hepatic Steatosis.","Inclusion Criteria:\n\n1. Men and women between 18 and 55 years old.\n2. High consumption of essential fatty acids (EFAs) \\> 8000 KU.\n3. With metabolic hepatic steatosis (MetHS) of any degree.\n4. Not currently undergoing nutritional treatment.\n5. Sedentary lifestyle.\n6. Denies alcoholism.\n7. Not taking any medications.\n8. No other health conditions.\n\nExclusion Criteria:\n\n1. Men and women undergoing treatment for metabolic diseases.\n2. Men and women with cardiovascular and\u002For coronary diseases.\n3. Pregnant women.\n4. Men and women undergoing hormone therapy.\n5. Men and women taking dietary supplements.\n6. Men and women who refuse to sign the informed consent form.\n7. In cases where space-occupying masses (tumors) are detected during the ultrasound.","ALL","18 Years","55 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"NA","Introduction. Advanced glycation end products, known as AGEs, are compounds that form when sugars bind uncontrollably to proteins, fats, or DNA. This occurs naturally in the body, but they also form in food, especially when cooked at high temperatures. Techniques such as grilling, frying, browning, or toasting increase AGE formation in food.\n\nProcessed foods or those dry-heated above 160 °C often contain many AGEs. When we consume them, about 10% of these AGEs can be absorbed by the body. Among the most studied types of AGEs are CML (N-6-carboxymethyl lysine) and pentosidine; these compounds have been found in the blood and liver of people and animals with metabolic hepatic steatosis (METS), a disease characterized by the accumulation of fat in the liver.\n\nWhen the body doesn't respond well to insulin and there are problems processing fats and sugars, the formation of AGEs is favored, which in turn can damage the liver. AGEs act by binding to receptors called RAGE; this binding activates various signals within cells that promote inflammation. Both RAGE and its soluble form (sRAGE) are important in metabolic syndrome (MetS). The AGE-RAGE interaction can contribute to the accumulation of more fat in the liver and help the disease progress to more severe stages.\n\nThe aim of this study is to evaluate whether a low-AGE diet improves liver function and reduces the amount of fat in the liver in adults with fatty liver not related to alcohol consumption.\n\nOur hypothesis is that implementing a low-AGE diet will improve liver function and decrease the degree of steatosis in adults with fatty liver not related to alcohol consumption.\n\nA clinical trial will be conducted comparing two groups. Forty-eight people who consume high amounts of AGEs (more than 8,000 KU) and have fatty liver of any grade will participate. Participants will be randomly assigned to one of two groups: one will follow an AGE-restricted diet, and the other will maintain their usual diet, for 12 weeks.\n\nBefore and after the study, the following measurements will be recorded: weight, height, waist circumference, hip circumference, abdominal circumference, and blood pressure. Fasting blood samples will also be taken to measure glucose (blood sugar), insulin, triglycerides, total cholesterol, HDL, LDL, AGE levels, glycated hemoglobin (which measures the average blood sugar level), and tests to evaluate liver function.",[27],"MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)",[29,30,31],"liver function","dietary AGEs","metabolic hepatic steatosis","NOT_YET_RECRUITING","2026-07-20",{"date":35,"type":36},"2026-07-23","ACTUAL",{"date":38,"type":21},"2026-08-11",{"date":40,"type":21},"2026-12-15",{"name":42,"class":43},"Universidad de Guanajuato","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100621578","photobiomodulation-in-the-prevention-and-management-of-oral-mucositis-in-children-100621578","NCT07372443","Photobiomodulation in the Prevention and Management of Oral Mucositis in Children","Usefulness of Photobio-modulation in the Prevention and Management of Oral Mucositis in Pediatric Patients Undergoing Antineoplastic Treatment: Randomized Clinical Trial","PBMOM-PEDMX","Inclusion Criteria:\n\nPrevention Arm - Inclusion Criteria\n\n* Age 4 to 17 years\n* Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.\n* Within days 1-3 of the start of any chemotherapy cycle; for leukemia patients, in consolidation phase as defined by protocol.\n* No signs of oral mucositis at enrollment.\n* Availability and willingness to attend scheduled photobiomodulation (PBM) application sessions.\n* Parent\u002Flegal guardian signed informed consent and child assent when applicable (≥ 8 years).\n* No documented primary immunodeficiency.\n* No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.\n* No PBM treatment within 14 days prior to enrollment.\n* No history of adverse reactions to light therapies or known photosensitivity.\n* No history of seizure disorder or diagnosis of epilepsy.\n\nTreatment Arm - Inclusion Criteria\n\n* Age 4 to 17 years\n* Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.\n* Currently receiving chemotherapy (any cycle of the regimen).\n* Presence of oral mucositis of any grade during chemotherapy, identified within the first 3 days from onset of the mucositis episode.\n* Parent\u002Flegal guardian signed informed consent and child assent when applicable (≥ 8 years).\n* No documented primary immunodeficiency.\n* No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.\n* No photobiomodulation (PBM) treatment within 14 days prior to enrollment.\n* No history of adverse reactions to light therapies or known photosensitivity.\n* No history of seizure disorder or diagnosis of epilepsy.\n\nExclusion Criteria:\n\n* Documented primary immunodeficiency.\n* Severe concomitant systemic infection or unstable medical condition.\n* PBM treatment within 14 days prior to enrollment.\n* Known photosensitivity or prior adverse reaction to light therapy.\n* History of seizures or epilepsy.\n* Any condition that, in the investigator's opinion, would interfere with study participation or safety.\n\nParticipant Withdrawal Criteria\n\n* Attendance to fewer than 80% of scheduled treatment sessions.\n* Any adverse event or persistent discomfort attributed to PBM that leads the participant or guardian to decline further intervention.\n* Withdrawal of consent by parent\u002Fguardian or assent withdrawal by participant when applicable.\n* Development of a new medical condition that, per investigator judgment, contraindicates continuation.","4 Years","17 Years",{"count":56,"type":21},49,[24],"Oral mucositis (OM) is a frequent, debilitating complication in pediatric oncology that impairs quality of life, nutrition, hydration, and treatment adherence. This randomized, prospective, single blind trial in Mexico will evaluate photobiomodulation (PBM) versus a conventional bioadhesive gel for prevention and treatment of antineoplastic therapy-induced OM in children aged 4-17 with leukemia, lymphoma, or head and neck tumors. A total of 49 participants will be enrolled. The study has two components: (1) Treatment - parallel comparison of PBM versus bioadhesive gel for established OM; (2) Prevention - crossover design in which patients receive both interventions across successive chemotherapy cycles. PBM will be delivered with a 660 nm device, 40 mW, 10 J\u002Fcm². The primary outcome is OM grade by the WHO scale assessed on days 7, 11, 14, and 21. Expected results include reduced OM incidence, severity, duration, and pain with favorable safety and tolerability, supporting standardized PBM protocols in pediatric oncology in Mexico.",[60,61,62],"Oral Mucositis","Chemotherapy Effect","Pediatric Cancer",[64],"Photobiomodulation","2026-01-19",{"date":67,"type":36},"2026-01-28",{"date":69,"type":21},"2026-01",{"date":71,"type":21},"2027-08",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100567360","phase-1-effects-of-low-intensity-transcranial-magnetic-stimulation-on-major-depressive-disorder-and-on-5-hydroxyindoleacetic-acid-and-brain-derived-neurotrophic-factor-levels-100567360","NCT06667180","Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels","Inclusion Criteria:\n\n* Age between 18 and 60 years.\n* Both sexes.\n* Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes).\n* Those who continue with their respective treatment and attend follow-up consultations at the health facility.\n* Those who do not have a history of epilepsy, schizophrenia, neurosurgeries.\n* Those who do not have metal plates anywhere in the skull, neck, chest and shoulder.\n* Those who do not use pacemakers.\n* Those who do not take hormone substitutes.\n* Those who agree to participate in the research.\n\nExclusion Criteria:\n\n* Those who are pregnant.","60 Years",{"count":81,"type":21},40,[83,84],"PHASE1","PHASE2","The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder. Final metabolites of serotonin such as 5-HIAA and growth factors such as BDNF will also be studied before starting the intervention and at the end to check if there is a significant change in their concentration. Likewise, its safety will be evaluated by monitoring the symptoms that they present at the end of the intervention and one month later. The main questions that are intended to be answered are:\n\n* Does low-intensity TMS reduce depressive symptoms in patients with MDD?\n* Does low-intensity TMS significantly change the initial and final concentrations of 5-HIAA and BDNF?\n* What adverse effects might patients who are exposed to low-intensity TMS experience? The researchers will compare low-intensity and accelerated TMS with sham TMS to see if low-intensity TMS works to treat MDD.\n\nParticipants:\n\n* Will undergo an initial clinical assessment to confirm the disorder, comorbidities, and general health status.\n* A 5 mL blood sample will be taken before starting the intervention.\n* Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 milliTesla (mT) and frequency of 50 Hz in theta bursts. Symptoms will be monitored daily.\n* A 5 mL blood sample will be taken at the end of the intervention and general health status clinimetrics will be reapplied.",[87,88,89],"Depression - Major Depressive Disorder","Transcranial Magnetic Stimulation","Placebo",[91,92,93,94,95],"accelerated low-intensity transcranial magnetic stimulation","Major depressive disorder","depression","brain-derived neurotrophic factor","5-hydroxyindoleacetic acid","RECRUITING","2025-05-05",{"date":99,"type":36},"2025-05-08",{"date":101,"type":36},"2024-10-28",{"date":103,"type":21},"2025-08-26",{"name":42,"class":43},""]